Resources from the same session
From SERMs to SERDs: Advances and challenges in the development of novel agents (focus on biomarkers)
Presenter: Otto Metzger
Session: Targeted options for advanced luminal breast cancers
Resources:
Slides
Webcast
Luminal HER2 positive vs luminal HER2 negative: Different drivers of endocrine resistance and the role of CDK4/6 inhibitors
Presenter: Luca Malorni
Session: Targeted options for advanced luminal breast cancers
Resources:
Slides
Webcast
Digital interactions in the management of targeted treatment
Presenter: Ines Vaz Luis
Session: Targeted options for advanced luminal breast cancers
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Targeted options for advanced luminal breast cancers
Resources:
Webcast